Company intelligence / Profile preview

Cytran

Ownership: Private
Development stage: Preclinical

Overview

Cytran developed peptide-based immunostimulants and small molecules targeting immune modulation and potassium channels. Its lead program IM862 failed to meet efficacy endpoints in a Phase 3 trial for AIDS-related Kaposi’s sarcoma but showed safety. The company explored further combination studies but has not reported recent activity or new results since the early 2000s.

Therapeutic areas: OtherOphthalmologyOncologyImmunology
Modalities: Small moleculePeptidesImmunostimulant (peptide-based)
Industry: Biotech

Beyond the preview

Go deeper on Cytran.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytran.

Explore the full profile